- RIUMA Principal
- Listar por autor
Listar por autor "Urbaneja, Patricia"
Mostrando ítems 1-7 de 7
-
Activation of the JAK-STAT Signaling Pathway after In Vitro Stimulation with IFN beta in Multiple Sclerosis Patients According to the Therapeutic Response to IFN beta
Hurtado-Guerrero, Isaac; Pinto-Medel, María-Jesús; Urbaneja, Patricia; Rodríguez-Bada, José Luis; León, Antonio; Guerrero, Miguel; Fernández-Fernández, Óscar; Leyva-Fernández, Laura; Oliver-Martos, Begoña[et al.] (Public Library of Science, 2017)Interferon beta (IFNß) is a common treatment used for multiple sclerosis (MS) which acts through the activation of the JAK-STAT pathway. However, this therapy is not always effective and currently there are no reliable ... -
Antiviral, Immunomodulatory and Antiproliferative Activities of Recombinant Soluble IFNAR2 without IFN-ß Mediation
Hurtado-Guerrero, Isaac; Hernáez, Bruno; Pinto-Medel, Maria Jesús; Calonge, Esther; Rodríguez-Bada, José Luis; Urbaneja, Patricia; Alonso, Ana; Mena-Vázquez, Natalia; Aliaga, Pablo; Issazadeh-Navikas, Shohreh; Pavía-Molina, José; Leyva-Fernández, Laura; Alcamí, José; Alcamí, Antonio; Fernández-Fernández, Óscar; Oliver-Martos, Begoña[et al.] (MDPI, 2020)Soluble receptors of cytokines are able to modify cytokine activities and therefore the immune system, and some have intrinsic biological activities without mediation from their cytokines. The soluble interferon beta (IFN-ß) ... -
Cross-reactivity of antibodies against interferon beta in multiple sclerosis patients and interference of the JAK-STAT signaling pathway
Hurtado-Guerrero, Isaac; Pinto-Medel, Maria Jesus; Urbaneja, Patricia; Rodríguez-Bada, José Luis; Ortega-Pinazo, Jesús; Serrano-Castro, Pedro Jesús; Fernández-Fernández, Óscar; Leyva-Fernández, Laura; Oliver-Martos, Begoña[et al.] (Nature, 2017)Interferon beta (IFNβ) therapy has immunogenic properties and induces the development of neutralizing antibodies (NAbs). From the extensive literature focused in the development of NAbs in multiple sclerosis (MS) patients, ... -
Decreased soluble IFN-β receptor (sIFNAR2) in multiple sclerosis patients: A potential serum diagnostic biomarker
Órpez-Zafra, Teresa; Pavía-Molina, José; Hurtado-Guerrero, Isaac; Pinto-Medel, Maria Jesús; Rodríguez-Bada, José Luis; Urbaneja, Patricia; Suardíaz García, Margarita; Villar, Luisa M; Comabella, Manuel; Montalban, Xavier; Alvarez-Cermeño, Jose C; Leyva-Fernández, Laura; Fernández-Fernández, Óscar; Oliver-Martos, Begoña[et al.] (SAGE Journals, 2017)Background: The soluble isoform of the interferon-β (IFN-β) receptor (sIFNAR2) could modulate the activity of both endogenous and systemically administered IFN-β. Previously, we described lower serum sIFNAR2 levels in ... -
Early development of anti-natalizumab antibodies in MS patients
Oliver-Martos, Begoña; Órpez, Teresa; Urbaneja, Patricia; Maldonado-Sanchez, Rafael; Leyva-Fernández, Laura; Fernández Fernández, Óscar[et al.] (SpringerLink, 2013)The purpose of this study is to monitor the development of anti-natalizumab antibodies to evaluate their first appearance in multiple sclerosis patients, since their presence has been associated with a reduction in the ... -
Soluble Receptor Isoform of IFN-Beta (sIFNAR2) in Multiple Sclerosis Patients and Their Association With the Clinical Response to IFN-Beta Treatment
Aliaga-Gaspar, Pablo; Hurtado-Guerrero, Isaac; Ciano-Petersen, Nicolas Lundahl; Urbaneja, Patricia; Brichette Mieg, Isabel; Virginia Reyes, Virginia; Rodríguez-Bada, José Luis; Alvarez-Lafuente, Roberto; Arroyo, Rafael; Quintana, Ester; Ramió-Torrentà, Lluis; Alonso, Ana; Leyva-Fernández, Laura; Fernández-Fernández, Óscar; Oliver-Martos, Begoña[et al.] (2021-12)Protein and mRNA levels of sIFNAR2 increased after IFN-b treatment. According to the clinical response, only non-responders increased sIFNAR2 significantly at both protein and mRNA levels. sIFNAR2 gene expression correlated ... -
TRAIL and TRAIL receptors splice variants during long-term interferon β treatment of patients with multiple sclerosis: evaluation as biomarkers for therapeutic response
López-Gómez, Carlos; Oliver-Martos, Begoña; Pinto-Medel, María Jesús; Suardíaz García, Margarita; Reyes-Garrido, Virginia; Urbaneja, Patricia; Fernández-Fernández, Óscar; Leyva-Fernández, Laura[et al.] (BMJ Journals, 2016)Objective We aimed to assess the effects of interferon β (IFNβ) treatment on the expression of the splice variants of the Tumour necrosis factor-Related Apoptosis Inducing Ligand (TRAIL) and its receptors in different cell ...